| scholarly article | Q13442814 |
| P356 | DOI | 10.1007/S40291-020-00453-Y |
| P698 | PubMed publication ID | 32112368 |
| P2093 | author name string | Marc Hirschfeld | |
| Thalia Erbes | |||
| Andrea Ritter | |||
| Markus Jäger | |||
| Gerta Rücker | |||
| Daniela Weiß | |||
| Kai Berner | |||
| P2860 | cites work | Liquid biopsy: A new avenue in pathology | Q93370058 |
| microRNAs-107 inhibited autophagy, proliferation, and migration of breast cancer cells by targeting HMGB1 | Q95359386 | ||
| Methodological challenges in utilizing miRNAs as circulating biomarkers | Q27027950 | ||
| Breast Cancer Screening for Women at Average Risk: 2015 Guideline Update From the American Cancer Society | Q27347760 | ||
| Proteomic Analysis of Urine to Identify Breast Cancer Biomarker Candidates Using a Label-Free LC-MS/MS Approach | Q28550766 | ||
| Modulation of MicroRNA-194 and cell migration by HER2-targeting trastuzumab in breast cancer | Q28729012 | ||
| The MicroRNA Spectrum in 12 Body Fluids | Q29618068 | ||
| A tool for design of primers for microRNA-specific quantitative RT-qPCR | Q30571626 | ||
| Normalization of circulating microRNA expression data obtained by quantitative real-time RT-PCR | Q30984776 | ||
| MicroRNA in breast cancer: The association with BRCA1/2. | Q33364654 | ||
| Micromanaging vascular biology: tiny microRNAs play big band | Q33578296 | ||
| miR-376c promotes carcinogenesis and serves as a plasma marker for gastric carcinoma | Q33653161 | ||
| Micro-RNAs as Potential Predictors of Response to Breast Cancer Systemic Therapy: Future Clinical Implications | Q33838622 | ||
| Circulating microRNAs (miRNA) in serum of patients with prostate cancer | Q34182161 | ||
| miR-125b targets erythropoietin and its receptor and their expression correlates with metastatic potential and ERBB2/HER2 expression | Q34248579 | ||
| A genetic variant located in miR-423 is associated with reduced breast cancer risk | Q34275514 | ||
| Blood cell origin of circulating microRNAs: a cautionary note for cancer biomarker studies | Q34291952 | ||
| The crucial role of multiomic approach in cancer research and clinically relevant outcomes. | Q52363678 | ||
| Promotional effect of microRNA-194 on breast cancer cells via targeting F-box/WD repeat-containing protein 7. | Q52655150 | ||
| Pregnancy-associated breast cancer: the risky status quo and new concepts of predictive medicine. | Q52668260 | ||
| Identification of a metastasis-specific MicroRNA signature in human colorectal cancer | Q34461847 | ||
| Differential stability of cell-free circulating microRNAs: implications for their utilization as biomarkers | Q35000824 | ||
| miR-125b acts as a tumor suppressor in breast tumorigenesis via its novel direct targets ENPEP, CK2-α, CCNJ, and MEGF9. | Q35009302 | ||
| Feasibility of urinary microRNA detection in breast cancer patients and its potential as an innovative non-invasive biomarker | Q35247522 | ||
| Exosome and exosomal microRNA: trafficking, sorting, and function | Q35543884 | ||
| Mir-660 is downregulated in lung cancer patients and its replacement inhibits lung tumorigenesis by targeting MDM2-p53 interaction | Q35679203 | ||
| Next generation sequencing profiling identifies miR-574-3p and miR-660-5p as potential novel prognostic markers for breast cancer. | Q35791145 | ||
| Aberrant plasma levels of circulating miR-16, miR-107, miR-130a and miR-146a are associated with lymph node metastasis and receptor status of breast cancer patients | Q35955325 | ||
| MicroRNAs in body fluids--the mix of hormones and biomarkers | Q36176435 | ||
| The Impact of Hemolysis on Cell-Free microRNA Biomarkers | Q36872732 | ||
| miR-125b inhibited epithelial-mesenchymal transition of triple-negative breast cancer by targeting MAP2K7. | Q36891545 | ||
| Melanoma cell-derived exosomes promote epithelial-mesenchymal transition in primary melanocytes through paracrine/autocrine signaling in the tumor microenvironment | Q36907732 | ||
| MiRNA-107 inhibits proliferation and migration by targeting CDK8 in breast cancer | Q37516328 | ||
| Identification and validation of oncologic miRNA biomarkers for luminal A-like breast cancer. | Q37538598 | ||
| mir-660-p53-mir-486 Network: A New Key Regulatory Pathway in Lung Tumorigenesis | Q37631729 | ||
| Identification of a circulating microRNA signature to distinguish recurrence in breast cancer patients | Q37688228 | ||
| miR-424-5p promotes proliferation of gastric cancer by targeting Smad3 through TGF-β signaling pathway | Q37688919 | ||
| Elevated microRNA-125b levels predict a worse prognosis in HER2-positive breast cancer patients | Q37701109 | ||
| The LIN28/let-7 Pathway in Cancer. | Q37723361 | ||
| MicroRNA-222 Expression as a Predictive Marker for Tumor Progression in Hormone Receptor-Positive Breast Cancer | Q37735957 | ||
| microRNA detection in feces, sputum, pleural effusion and urine: novel tools for cancer screening (Review). | Q38113495 | ||
| Micro-RNAs and ovarian cancer: the state of art and perspectives of clinical research | Q38183485 | ||
| Technology in MicroRNA Profiling: Circulating MicroRNAs as Noninvasive Cancer Biomarkers in Breast Cancer | Q38294147 | ||
| Cancer biomarker detection: recent achievements and challenges | Q38367682 | ||
| Tracing Cellular Origin of Human Exosomes Using Multiplex Proximity Extension Assays | Q38374002 | ||
| Cancer survival in Africa, Asia, and Central America: a population-based study | Q38432918 | ||
| Liquid Biopsy: Current Status and Future Perspectives | Q38660130 | ||
| Pattern recognition for predictive, preventive, and personalized medicine in cancer. | Q38670423 | ||
| Urinary Exosomes: The Potential for Biomarker Utility, Intercellular Signaling and Therapeutics in Urological Malignancy | Q38682259 | ||
| miR-424(322)/503 is a breast cancer tumor suppressor whose loss promotes resistance to chemotherapy | Q38707925 | ||
| Inhibition of miR-660-5p expression suppresses tumor development and metastasis in human breast cancer | Q38714223 | ||
| Profiling cell-free and circulating miRNA: a clinical diagnostic tool for different cancers. | Q38718486 | ||
| MicroRNA-194 Promotes Prostate Cancer Metastasis by Inhibiting SOCS2. | Q38724560 | ||
| MiRNA-194 activates the Wnt/β-catenin signaling pathway in gastric cancer by targeting the negative Wnt regulator, SUFU. | Q38733212 | ||
| Potential diagnostic role of circulating MiRNAs in breast cancer: Implications on clinicopathological characters. | Q52717794 | ||
| The role of miR-125b-mitochondria-caspase-3 pathway in doxorubicin resistance and therapy in human breast cancer. | Q53220492 | ||
| Combination of serum miRNAs with Cyfra21-1 for the diagnosis of non-small cell lung cancer. | Q53407203 | ||
| Diagnostic value of circulating microRNAs as biomarkers for breast cancer: a meta-analysis study. | Q53420685 | ||
| Tumor microRNA expression profiling identifies circulating microRNAs for early breast cancer detection. | Q53474457 | ||
| A serum microRNA signature predicts tumor relapse and survival in triple-negative breast cancer patients. | Q53651538 | ||
| Characterization and deep sequencing analysis of exosomal and non-exosomal miRNA in human urine. | Q54420629 | ||
| miR-424-5p regulates cell proliferation, migration and invasion by targeting doublecortin-like kinase 1 in basal-like breast cancer. | Q54982047 | ||
| Update on the types and usage of liquid biopsies in the clinical setting: a systematic review. | Q55009692 | ||
| Nonredundant, Highly Connected MicroRNAs Control Functionality in Breast Cancer Networks. | Q55554998 | ||
| MicroRNA‑424 serves an anti‑oncogenic role by targeting cyclin‑dependent kinase 1 in breast cancer cells | Q57068624 | ||
| Knockdown of miR-194-5p inhibits cell proliferation, migration and invasion in breast cancer by regulating the Wnt/β-catenin signaling pathway | Q57069810 | ||
| Role of family microRNA in breast cancer | Q57119043 | ||
| Let-7 microRNA as a potential therapeutic target with implications for immunotherapy | Q57453171 | ||
| A urinary microRNA (miR) signature for diagnosis of bladder cancer | Q57473447 | ||
| Standardized Immunomonitoring: Separating the Signals from the Noise | Q57789209 | ||
| Interdisciplinary Screening, Diagnosis, Therapy and Follow-up of Breast Cancer. Guideline of the DGGG and the DKG (S3-Level, AWMF Registry Number 032/045OL, December 2017) - Part 1 with Recommendations for the Screening, Diagnosis and Therapy of Brea | Q58124814 | ||
| Inhibition of miR-423-5p suppressed prostate cancer through targeting GRIM-19 | Q58580252 | ||
| MiR-221/222 promote epithelial-mesenchymal transition by targeting Notch3 in breast cancer cell lines | Q58799543 | ||
| Searching for the Novel Specific Predictors of Prostate Cancer in Urine: The Analysis of 84 miRNA Expression | Q60951719 | ||
| MiRNA Polymorphisms and Cancer Prognosis: A Systematic Review and Meta-Analysis | Q60956729 | ||
| Epidemiological characteristics of and risk factors for breast cancer in the world | Q64058041 | ||
| Urine Biomarkers for the Early Detection of Ovarian Cancer - Are We There Yet? | Q64098954 | ||
| Detection of Volatile Organic Compounds (VOCs) in Urine via Gas Chromatography-Mass Spectrometry QTOF to Differentiate Between Localized and Metastatic Models of Breast Cancer | Q64122004 | ||
| let-7i inhibits proliferation and migration of bladder cancer cells by targeting HMGA1. | Q64999526 | ||
| Comparison of the performance of screening mammography, physical examination, and breast US and evaluation of factors that influence them: an analysis of 27,825 patient evaluations | Q78299914 | ||
| Urinary metallomics as a novel biomarker discovery platform: Breast cancer as a case study | Q86744040 | ||
| Early non-invasive detection of breast cancer using exhaled breath and urine analysis | Q88352884 | ||
| Expression Analysis of MicroRNA-222 in Breast Cancer | Q88606028 | ||
| Exosomal miR-423-5p targets SUFU to promote cancer growth and metastasis and serves as a novel marker for gastric cancer | Q88635678 | ||
| Exosome-mediated miR-222 transferring: An insight into NF-κB-mediated breast cancer metastasis | Q88737471 | ||
| A method for extracting and characterizing RNA from urine: For downstream PCR and RNAseq analysis | Q88765264 | ||
| Downregulation of microRNA‑660 inhibits cell proliferation and invasion in osteosarcoma by directly targeting forkhead box O1 | Q89099932 | ||
| MiR-17-5p may serve as a novel predictor for breast cancer recurrence | Q89140280 | ||
| Role of some circulating MiRNAs on breast cancer diagnosis | Q89168692 | ||
| Urine miRNA as a potential biomarker for bladder cancer detection - a meta-analysis | Q90431409 | ||
| miR-221/222 activate the Wnt/β-catenin signaling to promote triple-negative breast cancer | Q90570447 | ||
| Breast cancer incidence, mortality and mortality-to-incidence ratio (MIR) are associated with human development, 1990-2016: evidence from Global Burden of Disease Study 2016 | Q90859518 | ||
| Liquid biopsy in breast cancer: A comprehensive review | Q91173671 | ||
| Targets, pitfalls and reference materials for liquid biopsy tests in cancer diagnostics | Q91230442 | ||
| MULTIOMIC PATTERNS IN BODY FLUIDS: TECHNOLOGICAL CHALLENGE WITH A GREAT POTENTIAL TO IMPLEMENT THE ADVANCED PARADIGM OF 3P MEDICINE | Q91320423 | ||
| Breast Cancer in Young Women: Status Quo and Advanced Disease Management by a Predictive, Preventive, and Personalized Approach | Q91325479 | ||
| Circulating non‑coding RNA‑biomarker potential in neoadjuvant chemotherapy of triple negative breast cancer? | Q91596428 | ||
| Liquid biopsy and minimal residual disease - latest advances and implications for cure | Q91845060 | ||
| Promises and Pitfalls of Using Liquid Biopsy for Precision Medicine | Q92169784 | ||
| RNA N6-methyladenosine modification participates in miR-660/E2F3 axis-mediated inhibition of cell proliferation in gastric cancer | Q92633925 | ||
| Why the Gold Standard Approach by Mammography Demands Extension by Multiomics? Application of Liquid Biopsy miRNA Profiles to Breast Cancer Disease Management | Q92755500 | ||
| Tumor-derived extracellular vesicles in breast cancer: From bench to bedside | Q92986411 | ||
| LncRNA LINC00319 accelerates ovarian cancer progression through miR-423-5p/NACC1 pathway | Q93157463 | ||
| Expression of circulating miR-17, miR-25, and miR-133 in breast cancer patients | Q93369395 | ||
| Let‑7 miRNAs sensitize breast cancer stem cells to radiation‑induced repression through inhibition of the cyclin D1/Akt1/Wnt1 signaling pathway | Q38749109 | ||
| Cell-free microRNAs in blood and other body fluids, as cancer biomarkers. | Q38842894 | ||
| Diagnostic significance of circulating multiple miRNAs in breast cancer: a systematic review and meta-analysis | Q38845874 | ||
| MiR-107 down-regulates SIAH1 expression in human breast cancer cells and silencing of miR-107 inhibits tumor growth in a nude mouse model of triple-negative breast cancer | Q38889859 | ||
| miR-7 inhibits the invasion and metastasis of gastric cancer cells by suppressing epidermal growth factor receptor expression | Q39020619 | ||
| Circulating exosomes and exosomal microRNAs as biomarkers in gastrointestinal cancer. | Q39041043 | ||
| Entangling Relation of Micro RNA-let7, miRNA-200 and miRNA-125 with Various Cancers | Q39077807 | ||
| MicroRNA-194 suppresses prostate cancer migration and invasion by downregulating human nuclear distribution protein | Q39105580 | ||
| MicroRNA-424-5p suppresses the expression of SOCS6 in pancreatic cancer | Q39154906 | ||
| Repression of bone morphogenetic protein 4 by let-7i attenuates mesenchymal migration of head and neck cancer cells | Q39186516 | ||
| Circulating cell-free microRNAs as clinical cancer biomarkers | Q39266731 | ||
| Beyond circulating microRNA biomarkers: Urinary microRNAs in ovarian and breast cancer. | Q39274912 | ||
| Suppressed miR-424 expression via upregulation of target gene Chk1 contributes to the progression of cervical cancer | Q39370408 | ||
| Early Diagnosis of Breast Cancer | Q39415180 | ||
| Supernatant versus exosomal urinary microRNAs. Two fractions with different outcomes in gynaecological cancers | Q40240560 | ||
| Serum miR-21 and miR-125b as markers predicting neoadjuvant chemotherapy response and prognosis in stage II/III breast cancer | Q40241312 | ||
| MicroRNA-194 represses glioma cell epithelial‑to‑mesenchymal transition by targeting Bmi1. | Q40375732 | ||
| A circulating miRNA signature as a diagnostic biomarker for non-invasive early detection of breast cancer | Q40420399 | ||
| Relative levels of let-7a, miR-17, miR-27b, miR-125a, miR-125b and miR-206 as potential molecular markers to evaluate grade, receptor status and molecular type in breast cancer | Q40780273 | ||
| Genetic analysis and preliminary function study of miR-423 in breast cancer | Q41462082 | ||
| Discriminating patients with early-stage breast cancer from benign lesions by detection of oxidative DNA damage biomarker in urine | Q41593052 | ||
| Distribution of microRNA biomarker candidates in solid tissues and body fluids | Q41668862 | ||
| Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. | Q41689462 | ||
| Circulating microRNAs in breast cancer: novel diagnostic and prognostic biomarkers. | Q42122645 | ||
| A regulatory BMI1/let-7i/ERK3 pathway controls the motility of head and neck cancer cells | Q42244159 | ||
| Circulating microRNAs in patients with hormone receptor-positive, metastatic breast cancer treated with dovitinib. | Q42370321 | ||
| Differential expression of exosomal miRNAs between breast cancer patients with and without recurrence | Q42378394 | ||
| OncomiR-17-5p: alarm signal in cancer? | Q42378524 | ||
| Differential expression of miR-21, miR-125b and miR-191 in breast cancer tissue | Q43899072 | ||
| MicroRNA signatures in hereditary breast cancer | Q44685853 | ||
| miR-17-5p suppresses cell proliferation and invasion by targeting ETV1 in triple-negative breast cancer. | Q47101964 | ||
| Evaluation of miRNA-21 and miRNA Let-7 as Prognostic Markers in Patients With Breast Cancer. | Q47756820 | ||
| Search of MicroRNAs Regulating the Receptor Status of Breast Cancer In Silico and Experimental Confirmation of Their Expression in Tumors. | Q47929025 | ||
| Tumour-suppressive microRNA-424-5p directly targets CCNE1 as potential prognostic markers in epithelial ovarian cancer. | Q48140189 | ||
| Urinary microRNAs for prostate cancer diagnosis, prognosis, and treatment response: are we there yet? | Q48225109 | ||
| MicroRNA-107 is downregulated and having tumor suppressive effect in breast cancer by negatively regulating brain-derived neurotrophic factor | Q48440140 | ||
| Identification of a serum microRNA expression signature for detection of lung cancer, involving miR-23b, miR-221, miR-148b and miR-423-3p | Q49651668 | ||
| A Review of Physical Activity and Circulating miRNA Expression: Implications in Cancer Risk and Progression | Q49989138 | ||
| miR‑660‑5p is associated with cell migration, invasion, proliferation and apoptosis in renal cell carcinoma | Q50014279 | ||
| Exosomal miRNAs as novel cancer biomarkers: Challenges and opportunities | Q50091370 | ||
| Insights from the breast cancer screening trials: how screening affects the natural history of breast cancer and implications for evaluating service screening programs. | Q51033689 | ||
| PCR amplification on whole blood samples treated with different commonly used anticoagulants. | Q51161694 | ||
| Improved isolation strategies to increase the yield and purity of human urinary exosomes for biomarker discovery. | Q51736511 | ||
| Evaluation of several methodological challenges in circulating miRNA qPCR studies in patients with head and neck cancer. | Q51742589 | ||
| Generalized additive modeling with implicit variable selection by likelihood-based boosting. | Q51909164 | ||
| P433 | issue | 2 | |
| P921 | main subject | biomarker | Q864574 |
| P304 | page(s) | 215-232 | |
| P577 | publication date | 2020-04-01 | |
| P1433 | published in | Molecular Diagnosis and Therapy | Q15758832 |
| P1476 | title | Urinary Exosomal MicroRNAs as Potential Non-invasive Biomarkers in Breast Cancer Detection | |
| P478 | volume | 24 |
Search more.